Peter Bernhardt

Professor

University of Gothenburg

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Peter Bernhardt is a faculty member at the University of Gothenburg, Sweden. His research focuses on dosimetry and imaging techniques in nuclear medicine, particularly in the treatment of neuroendocrine tumors with radioimmunotherapy. Recent articles include evaluations of dosimetry for therapies using terbium-161 and lutetium-177, as well as advancements in imaging methods through deep learning. Professor Bernhardt is actively involved in bridging the gap between theoretical physics and clinical practice in radiation therapy.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2020

Collaborators (2)

Anna Sundlöv

Lund University

SWEDEN

View details

Johan Gustafsson

Lund University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Bernhardt

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Rethinking Dosimetry: A European Perspective.

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.

Evaluation of using small volume of interest regions for clinical kidney dosimetry in <sup>177</sup>Lu-DOTATATE treatments.

<sup>161</sup>Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas.

<sup>177</sup>Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE

First-in-human administration of [<sup>161</sup>Tb]Tb-SibuDAB and comparative dosimetry with standard [<sup>177</sup>Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

Dosimetric implications of kidney anatomical volume changes in <sup>177</sup>Lu-DOTATATE therapy.

Comparison of the tolerability of <sup>161</sup>Tb- and <sup>177</sup>Lu-labeled somatostatin analogues in the preclinical setting.

Improvements of <sup>177</sup>Lu SPECT images from sparsely acquired projections by reconstruction with deep-learning-generated synthetic projections.

Establishment of a clinical SPECT/CT protocol for imaging of 161Tb

Collaborators (2)

Anna Sundlöv

Johan Gustafsson

Make your next move.

Peter Bernhardt

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Rethinking Dosimetry: A European Perspective.

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.

Evaluation of using small volume of interest regions for clinical kidney dosimetry in &lt;sup&gt;177&lt;/sup&gt;Lu-DOTATATE treatments.

&lt;sup&gt;161&lt;/sup&gt;Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas.

&lt;sup&gt;177&lt;/sup&gt;Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE

First-in-human administration of [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-SibuDAB and comparative dosimetry with standard [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-I&amp;T as part of the PROGNOSTICS phase Ia study.

Dosimetric implications of kidney anatomical volume changes in <sup>177</sup>Lu-DOTATATE therapy.

Comparison of the tolerability of <sup>161</sup>Tb- and <sup>177</sup>Lu-labeled somatostatin analogues in the preclinical setting.

Improvements of <sup>177</sup>Lu SPECT images from sparsely acquired projections by reconstruction with deep-learning-generated synthetic projections.

Establishment of a clinical SPECT/CT protocol for imaging of 161Tb

Collaborators (2)

Anna Sundlöv

Johan Gustafsson

Make your next move.

Evaluation of using small volume of interest regions for clinical kidney dosimetry in <sup>177</sup>Lu-DOTATATE treatments.

<sup>161</sup>Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas.

<sup>177</sup>Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.

First-in-human administration of [<sup>161</sup>Tb]Tb-SibuDAB and comparative dosimetry with standard [<sup>177</sup>Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.